Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis
Status:
Terminated
Trial end date:
2020-06-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and
pharmacodynamics of multiple oral doses of DNL747 in subjects with Amyotrophic Lateral
Sclerosis in a cross-over design